Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial
Authors
Middleton, GBrock, K
Savage, J
Mant, R
Summers, Yvonne J
Connibear, J
Shah, R
Ottensmeier, C
Shaw, P
Lee, SM
Popat, S
Barrie, C
Barone, G
Billingham, L
Affiliation
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UKIssue Date
2020
Metadata
Show full item recordCitation
Medina M, Sander L, Moncada S. Endothelial dysfunction on cerebral small vessel disease. J Neurol Sci. 2019;405:71.Journal
Lancet Respiratory MedicineDOI
10.1016/s2213-2600(20)30033-3PubMed ID
32199466Additional Links
https://dx.doi.org/10.1016/s2213-2600(20)30033-3Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/s2213-2600(20)30033-3